InMed Pharmaceuticals (INM) shares ripped higher on May 19 as the company announced an all-stock merger with migraine drug developer Mentari Therapeutics.
The combined company will trade on Nasdaq under a new ticker symbol, with INM shareholders expected to own about 1.51% of it once the transaction closes.